Atezolizumab, an anti-programmed death-ligand 1 antibody, and bevacizumab, an anti-vascular endothelial growth factor antibody, were approved by the Food and Drug Administration (FDA) on May 2020 as a combination immunotherapy for patients with unresectable hepatocellular carcinoma (HCC) [1]. Here, VEGFA is linked to hepatocellular carcinoma.